These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 10822053)
1. Vasorelaxant effect of a phosphodiesterase 3 inhibitor, olprinone, on isolated human radial artery. Adachi H; Kamata S; Kodama K; Nagakura T Eur J Pharmacol; 2000 May; 396(1):43-7. PubMed ID: 10822053 [TBL] [Abstract][Full Text] [Related]
2. Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits. Fujimoto S; Ohashi M; Hiramoto A; Inoue Y; Nagai K; Shiokawa H; Itoh T Eur J Pharmacol; 1998 Jul; 353(2-3):239-46. PubMed ID: 9726653 [TBL] [Abstract][Full Text] [Related]
3. Differential vasodilation response to olprinone in rabbit renal and common carotid arteries. Minonishi T; Ogawa K; Tokinaga Y; Negoro T; Kimoto Y; Hatano Y J Anesth; 2010 Feb; 24(1):61-6. PubMed ID: 20175287 [TBL] [Abstract][Full Text] [Related]
4. Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery. Adachi H; Kakiki M; Kishi Y Eur J Pharmacol; 2005 Dec; 528(1-3):137-43. PubMed ID: 16325808 [TBL] [Abstract][Full Text] [Related]
5. Differential pharmacologic sensitivities of phosphodiesterase-3 inhibitors among human isolated gastroepiploic, internal mammary, and radial arteries. Onomoto M; Tsuneyoshi I; Yonetani A; Suehiro S; Matsumoto K; Sakata R; Kanmura Y Anesth Analg; 2005 Oct; 101(4):950-956. PubMed ID: 16192501 [TBL] [Abstract][Full Text] [Related]
6. Possible mechanisms underlying the vasodilatation induced by olprinone, a phosphodiesterase III inhibitor, in rabbit coronary artery. Ohashi M; Dohi Y; Itoh T Br J Pharmacol; 2000 Mar; 129(5):1000-6. PubMed ID: 10696101 [TBL] [Abstract][Full Text] [Related]
7. Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Mizushige K; Ueda T; Yukiiri K; Suzuki H Cardiovasc Drug Rev; 2002; 20(3):163-74. PubMed ID: 12397365 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts. Bethke T; Klimkiewicz A; Meyer W; Schumacher C; Schmitz W; Scholz H; Starbatty J; Wenzlaff H; Zimmermann W Arzneimittelforschung; 1995 Jul; 45(7):771-6. PubMed ID: 8573220 [TBL] [Abstract][Full Text] [Related]
9. Vasorelaxant effect of phosphodiesterase-inhibitor milrinone in the human radial artery used as coronary bypass graft. He GW; Yang CQ J Thorac Cardiovasc Surg; 2000 May; 119(5):1039-45. PubMed ID: 10788827 [TBL] [Abstract][Full Text] [Related]
10. Vasorelaxant effects of SCA40 (a phosphodiesterase III inhibitor) in pulmonary vascular preparations in rats. Crilley TK; Wanstall JC; Bonnet PA Clin Exp Pharmacol Physiol; 1998 May; 25(5):355-60. PubMed ID: 9612663 [TBL] [Abstract][Full Text] [Related]
11. Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor. Yu SM; Cheng ZJ; Kuo SC Eur J Pharmacol; 1995 Jun; 280(1):69-77. PubMed ID: 7498256 [TBL] [Abstract][Full Text] [Related]
12. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors. Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles. Ogawa T; Ohhara H; Tsunoda H; Kuroki J; Shoji T Arzneimittelforschung; 1989 Jan; 39(1):33-7. PubMed ID: 2566308 [TBL] [Abstract][Full Text] [Related]
14. Effects of saterinone and its enantiomers R(+)-saterinone and S(-)-saterinone on the phosphodiesterase isoenzymes from ventricular tissue of failing human hearts and porcine hearts. Zimmermann W; Scholz H; Schumacher C; Wenzlaff H; Haverich A Naunyn Schmiedebergs Arch Pharmacol; 1994 Jun; 349(6):611-8. PubMed ID: 7526225 [TBL] [Abstract][Full Text] [Related]
15. The effects of olprinone, a phosphodiesterase 3 inhibitor, on systemic and cerebral circulation. Ueda T; Mizushige K Curr Vasc Pharmacol; 2006 Jan; 4(1):1-7. PubMed ID: 16472171 [TBL] [Abstract][Full Text] [Related]
16. Effects of the new cardiotonic phosphodiesterase inhibitor 1,2-dihydro-5- imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3-pyridine-carbonitrile hydrochloride monohydrate on aortic input impedance. Kubota T; Itaya R; Todaka K; Sugimachi M; Sunagawa K; Takeshita A Arzneimittelforschung; 1991 Dec; 41(12):1211-5. PubMed ID: 1815518 [TBL] [Abstract][Full Text] [Related]
17. Effects of phosphodiesterase inhibitors after coronary artery bypass grafting. Orime Y; Shiono M; Hata H; Yagi S; Tsukamoto S; Okumura H; Kimura S; Hata M; Sezai A; Obana M; Sezai Y Jpn Circ J; 1999 Feb; 63(2):117-22. PubMed ID: 10084374 [TBL] [Abstract][Full Text] [Related]
18. Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. Mochida H; Inoue H; Takagi M; Noto T; Yano K; Kikkawa K Eur J Pharmacol; 2002 Apr; 440(1):45-52. PubMed ID: 11959087 [TBL] [Abstract][Full Text] [Related]
19. Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021. Miyahara M; Ito M; Itoh H; Shiraishi T; Isaka N; Konishi T; Nakano T Eur J Pharmacol; 1995 Sep; 284(1-2):25-33. PubMed ID: 8549633 [TBL] [Abstract][Full Text] [Related]